A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

Farhad Ravandi, Ivana Gojo, Mrinal M. Patnaik, Mark D. Minden, Hagop Kantarjian, Amy O. Johnson-Levonas, Craig Fancourt, Raymond Lam, Mary Beth Jones, Clayton D. Knox, Shelonitda Rose, Payal Shah Patel, Raoul Tibes

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)'. Together they form a unique fingerprint.

Medicine & Life Sciences